Results 41 to 50 of about 205,750 (304)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma

Radiation Oncology, 2019
Purpose Neoadjuvant chemoradiation or chemotherapy has improved the treatment efficacy of patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Qiancheng Hu, Dan Wang, Ye Chen, Xiaofen Li, Peng Cao, Dan Cao   +5 more
doaj   +1 more source

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities [PDF]

, 2017
© 2017 The Author(s). Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue echogenicity.
A Ahmed, A Guimond, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, B Banihashemi, B Fisher, B Ganeshan, BS Garra, BS Pio, BT Hennessy, C-P Chou, D Sethi, DA Mankoff, EJ Feleppa, EJ Feleppa, F Tixier, FJ Esteva, FL Lizzi, FT D’Astous, G Berger, G Minckwitz von, GJ Czarnota, GJ Czarnota, GN Hortobagyi, H Haibo, H Tadayyon, H Tadayyon, H Tadayyon, HC Kim, HM Kuerer, II Wistuba, J Czernin, JB Nikas, JPB O’Connor, K Brindle, K Sikora, K Suzuki, KA Wear, KM Brindle, KN Ogston, L Sannachi, LX Yao, M Dowsett, M Vaidya, MF Insana, ML Oelze, ML Oelze, N Duric, O Falou, O Falou, QH Huang, R Tiling, RM Haralick, RM Vlad, RM Vlad, SH Giordano, SH Giordano, SJ Cleator, SM Scholl, T Cover, TJ Larkin, U McDermott, V Goh, V Guarneri, X Li, Y Labyed   +70 more
core   +2 more sources

The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer

Current Oncology
The utility of neoadjuvant chemotherapy is expanding in the treatment of breast cancer. Although individual trials have shown comparable survival between patients receiving neoadjuvant and adjuvant chemotherapy, large-scale data analyses for outcomes in ...
Farhad Ghasemi, Muriel Brackstone
doaj   +1 more source

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens. [PDF]

, 2020
BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy.
Cabral, Howard, Jones, Eric, Ko, Naomi, Leproux, Anais, Mehta, Rita S, O'Sullivan, Thomas, Pera, Vivian, Peterson, Hannah M, Roblyer, Darren, Tabassum, Syeda, Tank, Anup, Tromberg, Bruce J   +11 more
core  

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer [PDF]

, 2017
. Background: To evaluate the treatment tolerance and clinical outcomes in patients aged 70 years and older with locally advanced oropharyngeal cancer treated by definitive intensity-modulated radiation therapy (IMRT).
Benevento, Ilaria, Bulzonetti, Nadia, Caiazzo, Rossella, DE FELICE, Francesca, Magnante, ANNA LISA, Musio, Daniela, Tombolini, Vincenzo   +6 more
core   +1 more source

Neoadjuvant chemotherapy in breast cancer

British Journal of Surgery, 2005
Abstract Background Neoadjuvant chemotherapy for breast cancer was originally used in locally advanced inoperable disease in order to achieve surgical resection. It was then extended to operable breast cancer with a view to downstaging tumours to facilitate breast-conserving surgery.
Charfare, H, Limongelli, S, Purushotham, A D   +2 more
openaire   +3 more sources

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis

World Journal of Surgical Oncology, 2021
Background Hepatectomy for resectable colorectal liver metastasis (CRLM) is recommended. However, the efficacy of upfront hepatectomy without neoadjuvant chemotherapy (NAC) is unclear due to the uncertainty of perioperative systemic chemotherapy ...
Kosuke Ono, Tomoyuki Abe, Akihiko Oshita, Yusuke Sumi, Takuya Yano, Hiroshi Okuda, Manabu Kurayoshi, Tsuyoshi Kobayashi, Hideki Ohdan, Toshio Noriyuki, Masahiro Nakahara   +10 more
doaj   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources

Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience

PLoS ONE, 2021
Introduction Neoadjuvant chemotherapy has become standard of care for cisplatin-eligible patients with muscle-invasive bladder cancer qualified to radical cystectomy, providing a modest increase in 5-year overall survival rate. Several regimens are being
Artur Lemiński, Krystian Kaczmarek, Tomasz Byrski, Marcin Słojewski   +3 more
doaj   +2 more sources